A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer
Status: NO_LONGER_AVAILABLE
Study type: EXPANDED_ACCESS
Conditions: Metastatic Breast Cancer
Interventions: DRUG: trastuzumab-MCC-DM1
Sponsor: Genentech, Inc.